Global (United States, European Union and China) Urinalysis Test

Urinalysis Test Comprehensive Study by Type (Dipstick Test, Visual Exam, Microscopic Exam), Indication (Urinary Tract Infection, Kidney Stones, Diabetes, Others), Technology (Fully Automated, Semi-automated), End-User (Hospitals, Clinical Laboratories, Home Care, Others) Players and Region - Global Market Outlook to 2030

Urinalysis Test Market by XX Submarkets | Forecast Years 2024-2030  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Urinalysis Test
A urinalysis is a common medical test that examines a person's urine to assess their overall health and detect various medical conditions. This test involves analyzing the physical, chemical, and microscopic properties of urine. Urinalysis can provide valuable information about the function of the kidneys and other organs, as well as help diagnose or monitor various medical conditions. The high prevalence of lifestyle-related diseases such as Urinary Tract Infections and Kidney stones drives the market for urinalysis tests market.

AttributesDetails
Study Period2018-2030
Base Year2023
UnitValue (USD Million)


Manufacturers invest in research and development to create advanced urinalysis test kits, automated systems, and point-of-care devices that offer improved accuracy, ease of use, and additional features. Apart from this companies undergo strategic activities such as acquisitions, mergers, collaboration, and partnerships along with new product launches to expand their product portfolio. Analyst at AMA Research estimates that United States Players will contribute the maximum growth to Global Urinalysis Test market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

Abbott (United States), Sysmex Corporation (Japan), Siemens Healthcare GmbH (Germany), Shenzhen Mindray Bio-Medical Electronics Co., Ltd. (China), F. Hoffmann-La Roche Ltd. (Switzerland), Quidel Corporation (United States), Bio-Rad Laboratories, Inc. (United States), Cardinal Health Inc. (United States), Beckman Coulter Inc. (United States), ACON Laboratories, Inc. (United States) and Danaher Corporation (United States) are some of the key players that are part of study coverage.

Segmentation Overview
AMA Research has segmented the market of Global Urinalysis Test market by Type (Dipstick Test, Visual Exam and Microscopic Exam) and Region.



On the basis of geography, the market of Urinalysis Test has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Indication, the sub-segment i.e. Urinary Tract Infection will boost the Urinalysis Test market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Technology, the sub-segment i.e. Fully Automated will boost the Urinalysis Test market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by End-User, the sub-segment i.e. Hospitals will boost the Urinalysis Test market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
Growing Adoption of Automation in Urinalysis Testing and Adoption of Telehealth and Remote Monitoring Solutions

Market Growth Drivers:
Increasing Prevalence of Life Style Related Diseases Such As Urinary Tract Infection and Kidney Stone and Growing Geriatric Population Drives the Market for Urinalysis Test Market

Challenges:
Stringent Regulatory Framework and High Coast Associated With Research and Development

Restraints:
Lack of Skilled Laboratory Technicians and Limited Availability of Advanced Equipment in Underdeveloped Countries Negatively Impact the Growth of the Market

Opportunities:
Large Patient Population and Increasing Disposable Income Play an Essential Role in Upgrading Laboratory Infrastructure

Market Leaders and their expansionary development strategies
In July 2018, Beckman Coulter, Inc. and ARKRAY, Inc. merged and launched iQ Urinalysis Workcell, and integrated automated urine analyzer
In January 2020, Sysmex invested in Astrego Diagnostics with a view to developing new urinalysis solutions for the primary care business. and In January 2019, Bio-Rad Laboratories, Inc., a provider of life science research and clinical diagnostics products, announced the launch of qUAntify Advance Control for use in clinical labs performing urinalysis testing.
The FDA is the primary regulatory authority responsible for the approval and regulation of medical devices and in vitro diagnostic tests in the United States, including urinalysis test kits and automated urinalysis systems. The FDA reviews and approves new urinalysis products for safety and effectiveness before they can be marketed and sold in the U.S. market.

Key Target Audience
Urinalysis Test Manufactures, Diagnostic Laboratories, Government Institutes, Regulatory Authorities, Potential Venture Capitalists and Investors, Research and Development Institutes, Market Research & Consulting Firms, End Users and Others

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Type
  • Dipstick Test
  • Visual Exam
  • Microscopic Exam
By Indication
  • Urinary Tract Infection
  • Kidney Stones
  • Diabetes
  • Others

By Technology
  • Fully Automated
  • Semi-automated

By End-User
  • Hospitals
  • Clinical Laboratories
  • Home Care
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Prevalence of Life Style Related Diseases Such As Urinary Tract Infection and Kidney Stone
      • 3.2.2. Growing Geriatric Population Drives the Market for Urinalysis Test Market
    • 3.3. Market Challenges
      • 3.3.1. Stringent Regulatory Framework and High Coast Associated With Research and Development
    • 3.4. Market Trends
      • 3.4.1. Growing Adoption of Automation in Urinalysis Testing
      • 3.4.2. Adoption of Telehealth and Remote Monitoring Solutions
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Urinalysis Test, by Type, Indication, Technology, End-User and Region (value) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Urinalysis Test (Value)
      • 5.2.1. Global Urinalysis Test by: Type (Value)
        • 5.2.1.1. Dipstick Test
        • 5.2.1.2. Visual Exam
        • 5.2.1.3. Microscopic Exam
      • 5.2.2. Global Urinalysis Test by: Indication (Value)
        • 5.2.2.1. Urinary Tract Infection
        • 5.2.2.2. Kidney Stones
        • 5.2.2.3. Diabetes
        • 5.2.2.4. Others
      • 5.2.3. Global Urinalysis Test by: Technology (Value)
        • 5.2.3.1. Fully Automated
        • 5.2.3.2. Semi-automated
      • 5.2.4. Global Urinalysis Test by: End-User (Value)
        • 5.2.4.1. Hospitals
        • 5.2.4.2. Clinical Laboratories
        • 5.2.4.3. Home Care
        • 5.2.4.4. Others
      • 5.2.5. Global Urinalysis Test Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
  • 6. Urinalysis Test: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Abbott (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Sysmex Corporation (Japan)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Siemens Healthcare GmbH (Germany)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Shenzhen Mindray Bio-Medical Electronics Co., Ltd. (China)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. F. Hoffmann-La Roche Ltd. (Switzerland)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Quidel Corporation (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Bio-Rad Laboratories, Inc. (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Cardinal Health Inc. (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Beckman Coulter Inc. (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. ACON Laboratories, Inc. (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Danaher Corporation (United States)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
  • 7. Global Urinalysis Test Sale, by Type, Indication, Technology, End-User and Region (value) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Urinalysis Test (Value)
      • 7.2.1. Global Urinalysis Test by: Type (Value)
        • 7.2.1.1. Dipstick Test
        • 7.2.1.2. Visual Exam
        • 7.2.1.3. Microscopic Exam
      • 7.2.2. Global Urinalysis Test by: Indication (Value)
        • 7.2.2.1. Urinary Tract Infection
        • 7.2.2.2. Kidney Stones
        • 7.2.2.3. Diabetes
        • 7.2.2.4. Others
      • 7.2.3. Global Urinalysis Test by: Technology (Value)
        • 7.2.3.1. Fully Automated
        • 7.2.3.2. Semi-automated
      • 7.2.4. Global Urinalysis Test by: End-User (Value)
        • 7.2.4.1. Hospitals
        • 7.2.4.2. Clinical Laboratories
        • 7.2.4.3. Home Care
        • 7.2.4.4. Others
      • 7.2.5. Global Urinalysis Test Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Urinalysis Test: by Type(USD Million)
  • Table 2. Urinalysis Test Dipstick Test , by Region USD Million (2018-2023)
  • Table 3. Urinalysis Test Visual Exam , by Region USD Million (2018-2023)
  • Table 4. Urinalysis Test Microscopic Exam , by Region USD Million (2018-2023)
  • Table 5. Urinalysis Test: by Indication(USD Million)
  • Table 6. Urinalysis Test Urinary Tract Infection , by Region USD Million (2018-2023)
  • Table 7. Urinalysis Test Kidney Stones , by Region USD Million (2018-2023)
  • Table 8. Urinalysis Test Diabetes , by Region USD Million (2018-2023)
  • Table 9. Urinalysis Test Others , by Region USD Million (2018-2023)
  • Table 10. Urinalysis Test: by Technology(USD Million)
  • Table 11. Urinalysis Test Fully Automated , by Region USD Million (2018-2023)
  • Table 12. Urinalysis Test Semi-automated , by Region USD Million (2018-2023)
  • Table 13. Urinalysis Test: by End-User(USD Million)
  • Table 14. Urinalysis Test Hospitals , by Region USD Million (2018-2023)
  • Table 15. Urinalysis Test Clinical Laboratories , by Region USD Million (2018-2023)
  • Table 16. Urinalysis Test Home Care , by Region USD Million (2018-2023)
  • Table 17. Urinalysis Test Others , by Region USD Million (2018-2023)
  • Table 18. South America Urinalysis Test, by Country USD Million (2018-2023)
  • Table 19. South America Urinalysis Test, by Type USD Million (2018-2023)
  • Table 20. South America Urinalysis Test, by Indication USD Million (2018-2023)
  • Table 21. South America Urinalysis Test, by Technology USD Million (2018-2023)
  • Table 22. South America Urinalysis Test, by End-User USD Million (2018-2023)
  • Table 23. Brazil Urinalysis Test, by Type USD Million (2018-2023)
  • Table 24. Brazil Urinalysis Test, by Indication USD Million (2018-2023)
  • Table 25. Brazil Urinalysis Test, by Technology USD Million (2018-2023)
  • Table 26. Brazil Urinalysis Test, by End-User USD Million (2018-2023)
  • Table 27. Argentina Urinalysis Test, by Type USD Million (2018-2023)
  • Table 28. Argentina Urinalysis Test, by Indication USD Million (2018-2023)
  • Table 29. Argentina Urinalysis Test, by Technology USD Million (2018-2023)
  • Table 30. Argentina Urinalysis Test, by End-User USD Million (2018-2023)
  • Table 31. Rest of South America Urinalysis Test, by Type USD Million (2018-2023)
  • Table 32. Rest of South America Urinalysis Test, by Indication USD Million (2018-2023)
  • Table 33. Rest of South America Urinalysis Test, by Technology USD Million (2018-2023)
  • Table 34. Rest of South America Urinalysis Test, by End-User USD Million (2018-2023)
  • Table 35. Asia Pacific Urinalysis Test, by Country USD Million (2018-2023)
  • Table 36. Asia Pacific Urinalysis Test, by Type USD Million (2018-2023)
  • Table 37. Asia Pacific Urinalysis Test, by Indication USD Million (2018-2023)
  • Table 38. Asia Pacific Urinalysis Test, by Technology USD Million (2018-2023)
  • Table 39. Asia Pacific Urinalysis Test, by End-User USD Million (2018-2023)
  • Table 40. China Urinalysis Test, by Type USD Million (2018-2023)
  • Table 41. China Urinalysis Test, by Indication USD Million (2018-2023)
  • Table 42. China Urinalysis Test, by Technology USD Million (2018-2023)
  • Table 43. China Urinalysis Test, by End-User USD Million (2018-2023)
  • Table 44. Japan Urinalysis Test, by Type USD Million (2018-2023)
  • Table 45. Japan Urinalysis Test, by Indication USD Million (2018-2023)
  • Table 46. Japan Urinalysis Test, by Technology USD Million (2018-2023)
  • Table 47. Japan Urinalysis Test, by End-User USD Million (2018-2023)
  • Table 48. India Urinalysis Test, by Type USD Million (2018-2023)
  • Table 49. India Urinalysis Test, by Indication USD Million (2018-2023)
  • Table 50. India Urinalysis Test, by Technology USD Million (2018-2023)
  • Table 51. India Urinalysis Test, by End-User USD Million (2018-2023)
  • Table 52. South Korea Urinalysis Test, by Type USD Million (2018-2023)
  • Table 53. South Korea Urinalysis Test, by Indication USD Million (2018-2023)
  • Table 54. South Korea Urinalysis Test, by Technology USD Million (2018-2023)
  • Table 55. South Korea Urinalysis Test, by End-User USD Million (2018-2023)
  • Table 56. Taiwan Urinalysis Test, by Type USD Million (2018-2023)
  • Table 57. Taiwan Urinalysis Test, by Indication USD Million (2018-2023)
  • Table 58. Taiwan Urinalysis Test, by Technology USD Million (2018-2023)
  • Table 59. Taiwan Urinalysis Test, by End-User USD Million (2018-2023)
  • Table 60. Australia Urinalysis Test, by Type USD Million (2018-2023)
  • Table 61. Australia Urinalysis Test, by Indication USD Million (2018-2023)
  • Table 62. Australia Urinalysis Test, by Technology USD Million (2018-2023)
  • Table 63. Australia Urinalysis Test, by End-User USD Million (2018-2023)
  • Table 64. Rest of Asia-Pacific Urinalysis Test, by Type USD Million (2018-2023)
  • Table 65. Rest of Asia-Pacific Urinalysis Test, by Indication USD Million (2018-2023)
  • Table 66. Rest of Asia-Pacific Urinalysis Test, by Technology USD Million (2018-2023)
  • Table 67. Rest of Asia-Pacific Urinalysis Test, by End-User USD Million (2018-2023)
  • Table 68. Europe Urinalysis Test, by Country USD Million (2018-2023)
  • Table 69. Europe Urinalysis Test, by Type USD Million (2018-2023)
  • Table 70. Europe Urinalysis Test, by Indication USD Million (2018-2023)
  • Table 71. Europe Urinalysis Test, by Technology USD Million (2018-2023)
  • Table 72. Europe Urinalysis Test, by End-User USD Million (2018-2023)
  • Table 73. Germany Urinalysis Test, by Type USD Million (2018-2023)
  • Table 74. Germany Urinalysis Test, by Indication USD Million (2018-2023)
  • Table 75. Germany Urinalysis Test, by Technology USD Million (2018-2023)
  • Table 76. Germany Urinalysis Test, by End-User USD Million (2018-2023)
  • Table 77. France Urinalysis Test, by Type USD Million (2018-2023)
  • Table 78. France Urinalysis Test, by Indication USD Million (2018-2023)
  • Table 79. France Urinalysis Test, by Technology USD Million (2018-2023)
  • Table 80. France Urinalysis Test, by End-User USD Million (2018-2023)
  • Table 81. Italy Urinalysis Test, by Type USD Million (2018-2023)
  • Table 82. Italy Urinalysis Test, by Indication USD Million (2018-2023)
  • Table 83. Italy Urinalysis Test, by Technology USD Million (2018-2023)
  • Table 84. Italy Urinalysis Test, by End-User USD Million (2018-2023)
  • Table 85. United Kingdom Urinalysis Test, by Type USD Million (2018-2023)
  • Table 86. United Kingdom Urinalysis Test, by Indication USD Million (2018-2023)
  • Table 87. United Kingdom Urinalysis Test, by Technology USD Million (2018-2023)
  • Table 88. United Kingdom Urinalysis Test, by End-User USD Million (2018-2023)
  • Table 89. Netherlands Urinalysis Test, by Type USD Million (2018-2023)
  • Table 90. Netherlands Urinalysis Test, by Indication USD Million (2018-2023)
  • Table 91. Netherlands Urinalysis Test, by Technology USD Million (2018-2023)
  • Table 92. Netherlands Urinalysis Test, by End-User USD Million (2018-2023)
  • Table 93. Rest of Europe Urinalysis Test, by Type USD Million (2018-2023)
  • Table 94. Rest of Europe Urinalysis Test, by Indication USD Million (2018-2023)
  • Table 95. Rest of Europe Urinalysis Test, by Technology USD Million (2018-2023)
  • Table 96. Rest of Europe Urinalysis Test, by End-User USD Million (2018-2023)
  • Table 97. MEA Urinalysis Test, by Country USD Million (2018-2023)
  • Table 98. MEA Urinalysis Test, by Type USD Million (2018-2023)
  • Table 99. MEA Urinalysis Test, by Indication USD Million (2018-2023)
  • Table 100. MEA Urinalysis Test, by Technology USD Million (2018-2023)
  • Table 101. MEA Urinalysis Test, by End-User USD Million (2018-2023)
  • Table 102. Middle East Urinalysis Test, by Type USD Million (2018-2023)
  • Table 103. Middle East Urinalysis Test, by Indication USD Million (2018-2023)
  • Table 104. Middle East Urinalysis Test, by Technology USD Million (2018-2023)
  • Table 105. Middle East Urinalysis Test, by End-User USD Million (2018-2023)
  • Table 106. Africa Urinalysis Test, by Type USD Million (2018-2023)
  • Table 107. Africa Urinalysis Test, by Indication USD Million (2018-2023)
  • Table 108. Africa Urinalysis Test, by Technology USD Million (2018-2023)
  • Table 109. Africa Urinalysis Test, by End-User USD Million (2018-2023)
  • Table 110. North America Urinalysis Test, by Country USD Million (2018-2023)
  • Table 111. North America Urinalysis Test, by Type USD Million (2018-2023)
  • Table 112. North America Urinalysis Test, by Indication USD Million (2018-2023)
  • Table 113. North America Urinalysis Test, by Technology USD Million (2018-2023)
  • Table 114. North America Urinalysis Test, by End-User USD Million (2018-2023)
  • Table 115. United States Urinalysis Test, by Type USD Million (2018-2023)
  • Table 116. United States Urinalysis Test, by Indication USD Million (2018-2023)
  • Table 117. United States Urinalysis Test, by Technology USD Million (2018-2023)
  • Table 118. United States Urinalysis Test, by End-User USD Million (2018-2023)
  • Table 119. Canada Urinalysis Test, by Type USD Million (2018-2023)
  • Table 120. Canada Urinalysis Test, by Indication USD Million (2018-2023)
  • Table 121. Canada Urinalysis Test, by Technology USD Million (2018-2023)
  • Table 122. Canada Urinalysis Test, by End-User USD Million (2018-2023)
  • Table 123. Mexico Urinalysis Test, by Type USD Million (2018-2023)
  • Table 124. Mexico Urinalysis Test, by Indication USD Million (2018-2023)
  • Table 125. Mexico Urinalysis Test, by Technology USD Million (2018-2023)
  • Table 126. Mexico Urinalysis Test, by End-User USD Million (2018-2023)
  • Table 127. Company Basic Information, Sales Area and Its Competitors
  • Table 128. Company Basic Information, Sales Area and Its Competitors
  • Table 129. Company Basic Information, Sales Area and Its Competitors
  • Table 130. Company Basic Information, Sales Area and Its Competitors
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Company Basic Information, Sales Area and Its Competitors
  • Table 136. Company Basic Information, Sales Area and Its Competitors
  • Table 137. Company Basic Information, Sales Area and Its Competitors
  • Table 138. Urinalysis Test: by Type(USD Million)
  • Table 139. Urinalysis Test Dipstick Test , by Region USD Million (2025-2030)
  • Table 140. Urinalysis Test Visual Exam , by Region USD Million (2025-2030)
  • Table 141. Urinalysis Test Microscopic Exam , by Region USD Million (2025-2030)
  • Table 142. Urinalysis Test: by Indication(USD Million)
  • Table 143. Urinalysis Test Urinary Tract Infection , by Region USD Million (2025-2030)
  • Table 144. Urinalysis Test Kidney Stones , by Region USD Million (2025-2030)
  • Table 145. Urinalysis Test Diabetes , by Region USD Million (2025-2030)
  • Table 146. Urinalysis Test Others , by Region USD Million (2025-2030)
  • Table 147. Urinalysis Test: by Technology(USD Million)
  • Table 148. Urinalysis Test Fully Automated , by Region USD Million (2025-2030)
  • Table 149. Urinalysis Test Semi-automated , by Region USD Million (2025-2030)
  • Table 150. Urinalysis Test: by End-User(USD Million)
  • Table 151. Urinalysis Test Hospitals , by Region USD Million (2025-2030)
  • Table 152. Urinalysis Test Clinical Laboratories , by Region USD Million (2025-2030)
  • Table 153. Urinalysis Test Home Care , by Region USD Million (2025-2030)
  • Table 154. Urinalysis Test Others , by Region USD Million (2025-2030)
  • Table 155. South America Urinalysis Test, by Country USD Million (2025-2030)
  • Table 156. South America Urinalysis Test, by Type USD Million (2025-2030)
  • Table 157. South America Urinalysis Test, by Indication USD Million (2025-2030)
  • Table 158. South America Urinalysis Test, by Technology USD Million (2025-2030)
  • Table 159. South America Urinalysis Test, by End-User USD Million (2025-2030)
  • Table 160. Brazil Urinalysis Test, by Type USD Million (2025-2030)
  • Table 161. Brazil Urinalysis Test, by Indication USD Million (2025-2030)
  • Table 162. Brazil Urinalysis Test, by Technology USD Million (2025-2030)
  • Table 163. Brazil Urinalysis Test, by End-User USD Million (2025-2030)
  • Table 164. Argentina Urinalysis Test, by Type USD Million (2025-2030)
  • Table 165. Argentina Urinalysis Test, by Indication USD Million (2025-2030)
  • Table 166. Argentina Urinalysis Test, by Technology USD Million (2025-2030)
  • Table 167. Argentina Urinalysis Test, by End-User USD Million (2025-2030)
  • Table 168. Rest of South America Urinalysis Test, by Type USD Million (2025-2030)
  • Table 169. Rest of South America Urinalysis Test, by Indication USD Million (2025-2030)
  • Table 170. Rest of South America Urinalysis Test, by Technology USD Million (2025-2030)
  • Table 171. Rest of South America Urinalysis Test, by End-User USD Million (2025-2030)
  • Table 172. Asia Pacific Urinalysis Test, by Country USD Million (2025-2030)
  • Table 173. Asia Pacific Urinalysis Test, by Type USD Million (2025-2030)
  • Table 174. Asia Pacific Urinalysis Test, by Indication USD Million (2025-2030)
  • Table 175. Asia Pacific Urinalysis Test, by Technology USD Million (2025-2030)
  • Table 176. Asia Pacific Urinalysis Test, by End-User USD Million (2025-2030)
  • Table 177. China Urinalysis Test, by Type USD Million (2025-2030)
  • Table 178. China Urinalysis Test, by Indication USD Million (2025-2030)
  • Table 179. China Urinalysis Test, by Technology USD Million (2025-2030)
  • Table 180. China Urinalysis Test, by End-User USD Million (2025-2030)
  • Table 181. Japan Urinalysis Test, by Type USD Million (2025-2030)
  • Table 182. Japan Urinalysis Test, by Indication USD Million (2025-2030)
  • Table 183. Japan Urinalysis Test, by Technology USD Million (2025-2030)
  • Table 184. Japan Urinalysis Test, by End-User USD Million (2025-2030)
  • Table 185. India Urinalysis Test, by Type USD Million (2025-2030)
  • Table 186. India Urinalysis Test, by Indication USD Million (2025-2030)
  • Table 187. India Urinalysis Test, by Technology USD Million (2025-2030)
  • Table 188. India Urinalysis Test, by End-User USD Million (2025-2030)
  • Table 189. South Korea Urinalysis Test, by Type USD Million (2025-2030)
  • Table 190. South Korea Urinalysis Test, by Indication USD Million (2025-2030)
  • Table 191. South Korea Urinalysis Test, by Technology USD Million (2025-2030)
  • Table 192. South Korea Urinalysis Test, by End-User USD Million (2025-2030)
  • Table 193. Taiwan Urinalysis Test, by Type USD Million (2025-2030)
  • Table 194. Taiwan Urinalysis Test, by Indication USD Million (2025-2030)
  • Table 195. Taiwan Urinalysis Test, by Technology USD Million (2025-2030)
  • Table 196. Taiwan Urinalysis Test, by End-User USD Million (2025-2030)
  • Table 197. Australia Urinalysis Test, by Type USD Million (2025-2030)
  • Table 198. Australia Urinalysis Test, by Indication USD Million (2025-2030)
  • Table 199. Australia Urinalysis Test, by Technology USD Million (2025-2030)
  • Table 200. Australia Urinalysis Test, by End-User USD Million (2025-2030)
  • Table 201. Rest of Asia-Pacific Urinalysis Test, by Type USD Million (2025-2030)
  • Table 202. Rest of Asia-Pacific Urinalysis Test, by Indication USD Million (2025-2030)
  • Table 203. Rest of Asia-Pacific Urinalysis Test, by Technology USD Million (2025-2030)
  • Table 204. Rest of Asia-Pacific Urinalysis Test, by End-User USD Million (2025-2030)
  • Table 205. Europe Urinalysis Test, by Country USD Million (2025-2030)
  • Table 206. Europe Urinalysis Test, by Type USD Million (2025-2030)
  • Table 207. Europe Urinalysis Test, by Indication USD Million (2025-2030)
  • Table 208. Europe Urinalysis Test, by Technology USD Million (2025-2030)
  • Table 209. Europe Urinalysis Test, by End-User USD Million (2025-2030)
  • Table 210. Germany Urinalysis Test, by Type USD Million (2025-2030)
  • Table 211. Germany Urinalysis Test, by Indication USD Million (2025-2030)
  • Table 212. Germany Urinalysis Test, by Technology USD Million (2025-2030)
  • Table 213. Germany Urinalysis Test, by End-User USD Million (2025-2030)
  • Table 214. France Urinalysis Test, by Type USD Million (2025-2030)
  • Table 215. France Urinalysis Test, by Indication USD Million (2025-2030)
  • Table 216. France Urinalysis Test, by Technology USD Million (2025-2030)
  • Table 217. France Urinalysis Test, by End-User USD Million (2025-2030)
  • Table 218. Italy Urinalysis Test, by Type USD Million (2025-2030)
  • Table 219. Italy Urinalysis Test, by Indication USD Million (2025-2030)
  • Table 220. Italy Urinalysis Test, by Technology USD Million (2025-2030)
  • Table 221. Italy Urinalysis Test, by End-User USD Million (2025-2030)
  • Table 222. United Kingdom Urinalysis Test, by Type USD Million (2025-2030)
  • Table 223. United Kingdom Urinalysis Test, by Indication USD Million (2025-2030)
  • Table 224. United Kingdom Urinalysis Test, by Technology USD Million (2025-2030)
  • Table 225. United Kingdom Urinalysis Test, by End-User USD Million (2025-2030)
  • Table 226. Netherlands Urinalysis Test, by Type USD Million (2025-2030)
  • Table 227. Netherlands Urinalysis Test, by Indication USD Million (2025-2030)
  • Table 228. Netherlands Urinalysis Test, by Technology USD Million (2025-2030)
  • Table 229. Netherlands Urinalysis Test, by End-User USD Million (2025-2030)
  • Table 230. Rest of Europe Urinalysis Test, by Type USD Million (2025-2030)
  • Table 231. Rest of Europe Urinalysis Test, by Indication USD Million (2025-2030)
  • Table 232. Rest of Europe Urinalysis Test, by Technology USD Million (2025-2030)
  • Table 233. Rest of Europe Urinalysis Test, by End-User USD Million (2025-2030)
  • Table 234. MEA Urinalysis Test, by Country USD Million (2025-2030)
  • Table 235. MEA Urinalysis Test, by Type USD Million (2025-2030)
  • Table 236. MEA Urinalysis Test, by Indication USD Million (2025-2030)
  • Table 237. MEA Urinalysis Test, by Technology USD Million (2025-2030)
  • Table 238. MEA Urinalysis Test, by End-User USD Million (2025-2030)
  • Table 239. Middle East Urinalysis Test, by Type USD Million (2025-2030)
  • Table 240. Middle East Urinalysis Test, by Indication USD Million (2025-2030)
  • Table 241. Middle East Urinalysis Test, by Technology USD Million (2025-2030)
  • Table 242. Middle East Urinalysis Test, by End-User USD Million (2025-2030)
  • Table 243. Africa Urinalysis Test, by Type USD Million (2025-2030)
  • Table 244. Africa Urinalysis Test, by Indication USD Million (2025-2030)
  • Table 245. Africa Urinalysis Test, by Technology USD Million (2025-2030)
  • Table 246. Africa Urinalysis Test, by End-User USD Million (2025-2030)
  • Table 247. North America Urinalysis Test, by Country USD Million (2025-2030)
  • Table 248. North America Urinalysis Test, by Type USD Million (2025-2030)
  • Table 249. North America Urinalysis Test, by Indication USD Million (2025-2030)
  • Table 250. North America Urinalysis Test, by Technology USD Million (2025-2030)
  • Table 251. North America Urinalysis Test, by End-User USD Million (2025-2030)
  • Table 252. United States Urinalysis Test, by Type USD Million (2025-2030)
  • Table 253. United States Urinalysis Test, by Indication USD Million (2025-2030)
  • Table 254. United States Urinalysis Test, by Technology USD Million (2025-2030)
  • Table 255. United States Urinalysis Test, by End-User USD Million (2025-2030)
  • Table 256. Canada Urinalysis Test, by Type USD Million (2025-2030)
  • Table 257. Canada Urinalysis Test, by Indication USD Million (2025-2030)
  • Table 258. Canada Urinalysis Test, by Technology USD Million (2025-2030)
  • Table 259. Canada Urinalysis Test, by End-User USD Million (2025-2030)
  • Table 260. Mexico Urinalysis Test, by Type USD Million (2025-2030)
  • Table 261. Mexico Urinalysis Test, by Indication USD Million (2025-2030)
  • Table 262. Mexico Urinalysis Test, by Technology USD Million (2025-2030)
  • Table 263. Mexico Urinalysis Test, by End-User USD Million (2025-2030)
  • Table 264. Research Programs/Design for This Report
  • Table 265. Key Data Information from Secondary Sources
  • Table 266. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Urinalysis Test: by Type USD Million (2018-2023)
  • Figure 5. Global Urinalysis Test: by Indication USD Million (2018-2023)
  • Figure 6. Global Urinalysis Test: by Technology USD Million (2018-2023)
  • Figure 7. Global Urinalysis Test: by End-User USD Million (2018-2023)
  • Figure 8. South America Urinalysis Test Share (%), by Country
  • Figure 9. Asia Pacific Urinalysis Test Share (%), by Country
  • Figure 10. Europe Urinalysis Test Share (%), by Country
  • Figure 11. MEA Urinalysis Test Share (%), by Country
  • Figure 12. North America Urinalysis Test Share (%), by Country
  • Figure 13. Global Urinalysis Test share by Players 2023 (%)
  • Figure 14. Global Urinalysis Test share by Players (Top 3) 2023(%)
  • Figure 15. Global Urinalysis Test share by Players (Top 5) 2023(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. Abbott (United States) Revenue, Net Income and Gross profit
  • Figure 18. Abbott (United States) Revenue: by Geography 2023
  • Figure 19. Sysmex Corporation (Japan) Revenue, Net Income and Gross profit
  • Figure 20. Sysmex Corporation (Japan) Revenue: by Geography 2023
  • Figure 21. Siemens Healthcare GmbH (Germany) Revenue, Net Income and Gross profit
  • Figure 22. Siemens Healthcare GmbH (Germany) Revenue: by Geography 2023
  • Figure 23. Shenzhen Mindray Bio-Medical Electronics Co., Ltd. (China) Revenue, Net Income and Gross profit
  • Figure 24. Shenzhen Mindray Bio-Medical Electronics Co., Ltd. (China) Revenue: by Geography 2023
  • Figure 25. F. Hoffmann-La Roche Ltd. (Switzerland) Revenue, Net Income and Gross profit
  • Figure 26. F. Hoffmann-La Roche Ltd. (Switzerland) Revenue: by Geography 2023
  • Figure 27. Quidel Corporation (United States) Revenue, Net Income and Gross profit
  • Figure 28. Quidel Corporation (United States) Revenue: by Geography 2023
  • Figure 29. Bio-Rad Laboratories, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 30. Bio-Rad Laboratories, Inc. (United States) Revenue: by Geography 2023
  • Figure 31. Cardinal Health Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 32. Cardinal Health Inc. (United States) Revenue: by Geography 2023
  • Figure 33. Beckman Coulter Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 34. Beckman Coulter Inc. (United States) Revenue: by Geography 2023
  • Figure 35. ACON Laboratories, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 36. ACON Laboratories, Inc. (United States) Revenue: by Geography 2023
  • Figure 37. Danaher Corporation (United States) Revenue, Net Income and Gross profit
  • Figure 38. Danaher Corporation (United States) Revenue: by Geography 2023
  • Figure 39. Global Urinalysis Test: by Type USD Million (2025-2030)
  • Figure 40. Global Urinalysis Test: by Indication USD Million (2025-2030)
  • Figure 41. Global Urinalysis Test: by Technology USD Million (2025-2030)
  • Figure 42. Global Urinalysis Test: by End-User USD Million (2025-2030)
  • Figure 43. South America Urinalysis Test Share (%), by Country
  • Figure 44. Asia Pacific Urinalysis Test Share (%), by Country
  • Figure 45. Europe Urinalysis Test Share (%), by Country
  • Figure 46. MEA Urinalysis Test Share (%), by Country
  • Figure 47. North America Urinalysis Test Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Abbott (United States)
  • Sysmex Corporation (Japan)
  • Siemens Healthcare GmbH (Germany)
  • Shenzhen Mindray Bio-Medical Electronics Co., Ltd. (China)
  • F. Hoffmann-La Roche Ltd. (Switzerland)
  • Quidel Corporation (United States)
  • Bio-Rad Laboratories, Inc. (United States)
  • Cardinal Health Inc. (United States)
  • Beckman Coulter Inc. (United States)
  • ACON Laboratories, Inc. (United States)
  • Danaher Corporation (United States)
Select User Access Type

Key Highlights of Report


May 2024 231 Pages 57 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global (United States, European Union and China) Urinalysis Test Quantitative research analysis
Global (United States, European Union and China) Urinalysis Test Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as Abbott (United States), Sysmex Corporation (Japan), Siemens Healthcare GmbH (Germany), Shenzhen Mindray Bio-Medical Electronics Co., Ltd. (China), F. Hoffmann-La Roche Ltd. (Switzerland), Quidel Corporation (United States), Bio-Rad Laboratories, Inc. (United States), Cardinal Health Inc. (United States), Beckman Coulter Inc. (United States), ACON Laboratories, Inc. (United States) and Danaher Corporation (United States) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"Growing Adoption of Automation in Urinalysis Testing " is seen as one of major influencing trends for Urinalysis Test Market during projected period 2023-2030.
The Urinalysis Test market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global (United States, European Union and China) Urinalysis Test Report?

Have a Query? Click Here

Other Related Reports

Medical Dispatch Solution Comprehensive Study by Application (Hospital, Clinic, Research Institutes, Others), Software (Web-Based, On-premise), Components (Solutions, Services) Players and Region - ...
$ 3800
Neurodegenerative Drugs Comprehensive Study by Route of Administration (Oral, Injection, Transdermal, Others), Distribution Channel (Retail Pharmacy, Hospital Pharmacy, Online Pharmacy), Indication ...
$ 3800
Online Dietary Supplement Comprehensive Study by Type (Vitamins, Minerals, Herbal Products, Amino acids, Botanicals, Sports Nutrition), Application (Pharmaceuticals, Hospitals, Households), Forms (Dr...
$ 3800
Interventional Oncology Comprehensive Study by Cancer Type (Lung Cancer, Liver Cancer, Kidney Cancer, Other), Procedure Type (Ablation (Thermal Tumor Ablation, Non-Thermal Tumor Ablation ), Radiation...
$ 3350
Anti Diarrheal Drugs Comprehensive Study by Type (Prescription Drugs, OTC Drugs), Application (Children, Adults), Distribution Channel (Hospital, Pharmaceutical Clinics, Online Store) Players and Reg...
$ 3500
Ayurvedic Health and Personal Care Products Comprehensive Study by Type (Skin Care, Hair Care, Oral Care, Digestive Care, Others), Distribution Channels (Supermarkets and Hypermarkets, Drug Stores, S...
$ 3800